APUS (Apimeds Pharmaceuticals Us) Other Stockholders Equity: $8.11 Mil (As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Other Stockholders Equity?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Other Stockholders Equity is $8.11 Mil as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Apimeds Pharmaceuticals Us's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $8.11 Mil.

Apimeds Pharmaceuticals Us's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) and increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($8.11 Mil).

Apimeds Pharmaceuticals Us's annual Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Apimeds Pharmaceuticals Us Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Other Stockholders Equity Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 -0.00 -0.00 0.00 0.00

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 -0.00 0.00 8.11
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $8.11 Mil mean?
Apimeds Pharmaceuticals Us (APUS) has a Other Stockholders Equity of $8.11 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' Other Stockholders Equity too high?
Apimeds Pharmaceuticals Us' current Other Stockholders Equity is $8.11 Mil. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Other Stockholders Equity compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' Other Stockholders Equity of $8.11 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current Other Stockholders Equity is $8.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Other Stockholders Equity of $8.11 Mil. The current Other Stockholders Equity is $8.11 Mil. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Other Stockholders Equity is $8.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price